ArticleFrontiers in cardiovascular medicine2026
Cathepsin B ablation alleviates VSMC phenotypic switching by modulating alternative macrophage polarization through the NLRP3 signaling pathway.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The classical activation of pro-inflammatory macrophages contributes to neointimal hyperplasia by driving the excessive accumulation of phenotypically switched vascular smooth muscle cells (VSMCs), a process that underlies occlusive disorders such as atherosclerosis and restenosis. However, the impact of Cathepsin B (CTSB) on the regulation of macrophage polarization remains unclear. Methods and Results: Analysis of the Gene Expression Omnibus (GEO) database revealed a significant upregulation of CTSB in advanced human atherosclerotic plaques. Furthermore, a time-dependent increase in CTSB expression was observed in carotid arteries following vascular injury. At the cellular level, CTSB expression was markedly elevated in pro-inflammatory M1 macrophages but suppressed in resolving M2 macrophages. A loss-of-function approach, utilizing AdshCTSB-transfected bone marrow-derived macrophages (BMDMs), demonstrated that CTSB knockdown promotes a shift in polarization, repressing M1 markers while inducing those characteristic of the M2 phenotype. This CTSB-mediated polarization switch subsequently attenuated the proliferation and migration of VSMCs while promoting their differentiation. Mechanistically, we identified NLRP3 as a direct target of CTSB. Knockdown of CTSB suppressed the NLRP3 inflammasome, an effect mediated through the cGAS-STING signaling pathway. The functional significance of this pathway was confirmed, as the STING agonist DMXAA abolished the polarizing effects of CTSB silencing. Discussion: In conclusion, our findings suggest that CTSB inhibition represents a promising therapeutic strategy for mitigating intimal hyperplasia. This approach operates by favoring alternative macrophage polarization, which in turn attenuates VSMC phenotypic switching, a process that is partially mediated by the inactivation of the cGAS-STING-NLRP3 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.